TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
Promising Signs of Efficacy Achieved with TILT-123 in Combination with Tumor Infiltrating Lymphocytes Therapy (TILT-T215)
Helsinki, Finland – 8 December 2023: TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma (NTC04217473), in an oral presentation at the ESMO Immuno-Oncology Congress (ESMO-IO) in Geneva, Switzerland (6-8 December).
